Nothing Special   »   [go: up one dir, main page]

DK1414471T3 - Terapeutiske midler omfattende pro-apoptotiske proteiner - Google Patents

Terapeutiske midler omfattende pro-apoptotiske proteiner

Info

Publication number
DK1414471T3
DK1414471T3 DK02763328.8T DK02763328T DK1414471T3 DK 1414471 T3 DK1414471 T3 DK 1414471T3 DK 02763328 T DK02763328 T DK 02763328T DK 1414471 T3 DK1414471 T3 DK 1414471T3
Authority
DK
Denmark
Prior art keywords
pro
therapeutic agents
apoptotic proteins
apoptotic
proteins
Prior art date
Application number
DK02763328.8T
Other languages
English (en)
Inventor
Michael G Rosenblum
Yuying Liu
Original Assignee
Res Dev Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Dev Foundation filed Critical Res Dev Foundation
Application granted granted Critical
Publication of DK1414471T3 publication Critical patent/DK1414471T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6467—Granzymes, e.g. granzyme A (3.4.21.78); granzyme B (3.4.21.79)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
DK02763328.8T 2001-07-17 2002-07-17 Terapeutiske midler omfattende pro-apoptotiske proteiner DK1414471T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30609101P 2001-07-17 2001-07-17
US33288601P 2001-11-06 2001-11-06
US36036102P 2002-02-28 2002-02-28
PCT/US2002/023378 WO2003007889A2 (en) 2001-07-17 2002-07-17 Therapeutic agents comprising pro-apoptotic proteins

Publications (1)

Publication Number Publication Date
DK1414471T3 true DK1414471T3 (da) 2012-07-16

Family

ID=27405139

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02763328.8T DK1414471T3 (da) 2001-07-17 2002-07-17 Terapeutiske midler omfattende pro-apoptotiske proteiner

Country Status (11)

Country Link
US (5) US7101977B2 (da)
EP (1) EP1414471B1 (da)
JP (1) JP2004535202A (da)
KR (1) KR100891272B1 (da)
CN (1) CN1555268B (da)
AU (1) AU2002327310B2 (da)
CA (1) CA2454048C (da)
DK (1) DK1414471T3 (da)
IL (2) IL159894A0 (da)
NZ (1) NZ530582A (da)
WO (1) WO2003007889A2 (da)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE62496B1 (en) * 1990-04-19 1995-02-08 Res Dev Foundation Antibody conjugates for treatment of neoplastic disease
US6749853B1 (en) * 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
ES2223705T3 (es) * 1999-04-28 2005-03-01 Board Of Regents, The University Of Texas System Composiciones y metodos para el tratamiento de cancer mediante inhibi cion selectiva del vegf.
US6703020B1 (en) * 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
ES2292587T3 (es) * 2000-04-22 2008-03-16 Pharmedartis Gmbh Agentes apoptoticos.
ZA200305980B (en) 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
GB0113121D0 (en) 2001-05-30 2001-07-18 Univ Leeds Biologically active photosensitisers
DK1414471T3 (da) * 2001-07-17 2012-07-16 Res Dev Foundation Terapeutiske midler omfattende pro-apoptotiske proteiner
US20040013691A1 (en) * 2002-06-12 2004-01-22 Rosenblum Michael G. Immunotoxin as a therapeutic agent and uses thereof
PT1537204E (pt) * 2002-08-23 2010-05-05 Gabriele Multhoff Granzima b como um indutor da apoptose em células tumorais dependente de hsp70/péptidos hsp70
AU2003275173A1 (en) * 2002-09-25 2004-04-19 Board Of Regents, The University Of Texas System Endogenous granzyme b in human non-hematopoietic cells
US20060024289A1 (en) * 2002-10-02 2006-02-02 Ruggles Sandra W Cleavage of VEGF and VEGF receptor by wild-type and mutant proteases
US7601341B2 (en) * 2003-06-05 2009-10-13 Research Development Foundation Vascular endothelial growth factor fusion constructs used to inhibit osteoclastogenesis
CA2527984A1 (en) * 2003-06-05 2004-12-16 Research Development Foundation Vascular endothelial growth factor fusion constructs and uses thereof
ATE553189T1 (de) * 2004-01-16 2012-04-15 Fraunhofer Ges Forschung Immunokinasen
DK1718283T3 (da) * 2004-01-22 2013-04-22 Univ Miami Topisk co-enzyme Q10 formuleringer og fremgangsmåder for anvendelse.
CA2562729C (en) 2004-04-12 2013-11-12 Sandra Waugh Ruggles Cleavage of vegf and vegf receptor by wildtype and mutant mt-sp1
WO2006026451A2 (en) * 2004-08-26 2006-03-09 Children's Hospital Inc. Targeted expression of apoptosis-inducing genes for disease treatment
JP2008526889A (ja) * 2005-01-10 2008-07-24 リサーチ ディベロップメント ファウンデーション 癌治療のための標的化キメラ分子
AU2006210769A1 (en) * 2005-02-01 2006-08-10 Research Development Foundation BLyS fusion proteins for targeting BLyS receptor and methods for treatment of B-cell proliferative disorders
KR20070114324A (ko) * 2005-03-25 2007-11-30 글리카트 바이오테크놀로지 아게 Ｍｃｓｐ 에 향하며 증가된 ｆｃ 수용체 결합 친화도 및효과기 작용을 갖는 항원 결합 분자
US7893244B2 (en) * 2005-04-12 2011-02-22 Intradigm Corporation Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
MX2007012766A (es) * 2005-04-12 2008-10-01 Intradigm Corp Composición y métodos de terapéuticos de arni para el tratamiento de cáncer y otras enfermedades de neovascularización.
CA2606989A1 (en) * 2005-04-29 2006-11-09 Research Development Foundation Vascular targeting of ocular neovascularization
KR101393946B1 (ko) * 2005-10-21 2014-05-12 카탈리스트 바이오사이언시즈, 인코포레이티드 보체 활성화를 억제하는 변형된 프로테아제
EP1800695A1 (en) * 2005-12-21 2007-06-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Immuno-RNA-constructs
WO2007101202A1 (en) * 2006-02-27 2007-09-07 Research Development Foundation Cell-targeted ikb and methods for the use thereof
WO2007144882A2 (en) * 2006-06-14 2007-12-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Targeted chimeric proteins
EP2046375B1 (en) 2006-07-20 2017-04-05 The General Hospital Corporation Methods and compositions for the selective activation of protoxins through combinatorial targeting
EP2171456A2 (en) 2007-07-25 2010-04-07 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Self coupling recombinant antibody fusion proteins
WO2009081854A1 (ja) * 2007-12-21 2009-07-02 University Of Toyama アレルギー性疾患のバイオマーカーおよびその利用
ES2525065T3 (es) 2008-04-11 2014-12-17 Merrimack Pharmaceuticals, Inc. Ligadores de seroalbúmina humana y sus conjugados
EA023827B1 (ru) 2008-04-11 2016-07-29 БЕРГ ЭлЭлСи Способ индуцирования апоптоза в клетке
PT2322221E (pt) 2008-08-05 2014-09-19 Toray Industries Composição farmacêutica para tratamento e prevenção de cancro
WO2010016527A1 (ja) 2008-08-05 2010-02-11 東レ株式会社 癌の検出方法
KR20110112301A (ko) * 2008-11-18 2011-10-12 메리맥 파마슈티컬즈, 인크. 인간 혈청 알부민 링커 및 그 콘쥬게이트
WO2010075194A1 (en) * 2008-12-22 2010-07-01 St. Jude Children's Research Hospital Prokaryotic expression of soluble, active dkk
SG175993A1 (en) 2009-05-11 2011-12-29 Berg Biosystems Llc Methods for treatment of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
FR2949787A1 (fr) * 2009-09-09 2011-03-11 Centre Nat Rech Scient Molecules capables de perforer la mitochondrie et leurs applications
WO2011048589A2 (en) * 2009-10-23 2011-04-28 Ben Gurion University Of The Negev Research And Development Authority Ion exchangers and methods of use thereof
WO2011091398A1 (en) * 2010-01-25 2011-07-28 Abbott Laboratories Rapid characterization of proteins in complex biological fluids
US9267164B2 (en) 2010-09-26 2016-02-23 Da Yu Enterprises, L.L.C. Method of recombinant macromolecular production
AU2012240222B2 (en) 2011-04-04 2017-04-27 Berg Llc Methods of treating central nervous system tumors
PT2741085T (pt) 2011-08-04 2017-06-30 Toray Industries Método para a deteção de cancro prancreático
EP2755688A4 (en) * 2011-10-27 2014-08-06 Nkt Therapeutics Inc HUMANIZED ANTIBODIES AGAINST INKT
DK2818483T3 (da) 2012-02-21 2017-10-23 Toray Industries Medicinsk sammensætning til behandling og/eller forebyggelse af cancer
WO2013137328A1 (ja) * 2012-03-14 2013-09-19 Ｌｓｉｐファンド運営合同会社 抗がん剤のスクリーニング方法、並びにｇｒａｎｚｙｍｅ Ｍの活性を増大する物質を有効成分とする、細胞死を誘導する抗がん剤
PT2876447T (pt) 2012-07-19 2020-02-03 Toray Industries Método para deteção de cancro
CA2879304C (en) 2012-07-19 2020-07-14 Toray Industries, Inc. Method for detecting cancer
WO2014036520A1 (en) 2012-08-30 2014-03-06 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-erbb3 agents
EP4029937A1 (en) 2012-10-04 2022-07-20 Research Development Foundation Serine protease molecules and therapies
EP2730289A1 (en) * 2012-11-07 2014-05-14 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Novel immunoproteases
WO2014111553A1 (de) * 2013-01-17 2014-07-24 Sit Soft Intelligent Therapeutics Gmbh & Co Kg Selektives zelltod-induzierendes binäres enzymsystem
US10933032B2 (en) 2013-04-08 2021-03-02 Berg Llc Methods for the treatment of cancer using coenzyme Q10 combination therapies
ES2704909T3 (es) 2013-08-09 2019-03-20 Toray Industries Composición farmacéutica para el tratamiento y/o la prevención del cáncer
JP6595478B2 (ja) 2013-09-04 2019-10-23 バーグ エルエルシー コエンザイムｑ１０の連続注入によるがんの治療方法
KR102488961B1 (ko) * 2014-05-19 2023-01-16 삼성전자주식회사 그랜자임 b를 포함하는 융합 단백질 및 이의 용도
WO2017019729A1 (en) 2015-07-27 2017-02-02 The General Hospital Corporation Antibody derivatives with conditionally enabled effector function
EP3466444A4 (en) * 2016-06-02 2019-12-11 Riken ADJUVANT COMPOSITION AND USE THEREOF
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
TW201837467A (zh) 2017-03-01 2018-10-16 美商建南德克公司 用於癌症之診斷及治療方法
WO2019074842A1 (en) * 2017-10-09 2019-04-18 Keith Black ONCOLYTIC ANTICANCER IMMUNOTHERAPIES AND METHODS OF USE
US20220204575A1 (en) * 2019-04-23 2022-06-30 The Regents Of The University Of California Modulating survival of therapeutic cells and methods, cells and nucleic acids related thereto
CN115477705B (zh) * 2021-06-16 2024-02-23 四川大学华西医院 一种基于颗粒酶b构建的嵌合抗原受体免疫细胞制备及其应用
WO2024117543A1 (ko) * 2022-11-29 2024-06-06 주식회사 신렉스 암 세포 특이적 유전자 발현 시스템
WO2024205149A1 (ko) * 2023-03-24 2024-10-03 카오티에스 주식회사 신규한 그랜자임 융합단백질 및 이의 용도

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4263279A (en) 1975-08-19 1981-04-21 Yeda Research & Development Co. Ltd Pharmaceutically active compositions containing adriamycin and daunomycin
GB1564666A (en) 1978-05-31 1980-04-10 Ng Mun Hon Heterocomplexes of interferon with immunoglobulin and pharmaceutical compositions thereof
JPS5686121A (en) 1979-12-14 1981-07-13 Teijin Ltd Antitumor proten complex and its preparation
FR2504010B1 (fr) 1981-04-15 1985-10-25 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
US4522918A (en) 1981-12-15 1985-06-11 Jeffery Schlom Process for producing monoclonal antibodies reactive with human breast cancer
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
DE3483054D1 (de) 1983-03-04 1990-10-04 Health Research Inc Monoklonale antikoerper gegen humane brustkarzinomzellen und ihre verwendung in der diagnose und therapie.
FR2546756B1 (fr) 1983-06-03 1985-11-29 Centre Nat Rech Scient Nouveaux derives immunostimulants, leur preparation et leur application comme medicament
GB2148299B (en) 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
US4666845A (en) 1983-12-16 1987-05-19 Sloan-Kettering Institute Monoclonal antibodies to ovarian, cervical and uterine human cancers and method of diagnosis
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
US4753894A (en) 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
US4894443A (en) 1984-02-08 1990-01-16 Cetus Corporation Toxin conjugates
EP0160446B1 (en) 1984-05-01 1992-06-17 Ciba Corning Diagnostics Corp. Breast tumor-associated antigen and monoclonal antibodies specific thereto
FR2566271B1 (fr) 1984-06-20 1986-11-07 Sanofi Sa Nouveaux conjugues cytotoxiques utilisables en therapeutique et procede d'obtention
US4650674A (en) 1984-07-05 1987-03-17 Genentech, Inc. Synergistic cytotoxic composition
US4590071A (en) 1984-09-25 1986-05-20 Xoma Corporation Human melanoma specific immunotoxins
US4677064A (en) 1984-11-09 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4708930A (en) 1984-11-09 1987-11-24 Coulter Corporation Monoclonal antibody to a human carcinoma tumor associated antigen
ATE74382T1 (de) 1984-12-05 1992-04-15 Salk Inst For Biological Studi Monoklonaler antikoerper, spezifisch fuer brustkrebszelloberflaechenantigen.
US5032521A (en) 1984-12-05 1991-07-16 The Salk Institute For Biological Studies Monoclonal antibody specific for a mammary tumor cell surface antigen
CA1339798C (en) 1985-02-01 1998-04-07 Alan N. Houghton Method for treatment of neuroectodermal malignancies and epithelial carcinomas in humans
DE3581210D1 (de) 1985-03-04 1991-02-07 Dana Farber Cancer Inst Inc Immunotoxin und herstellung.
US4888415A (en) 1985-03-04 1989-12-19 Dana-Farber Cancer Institute, Inc. Gelonin immunotoxin
US6084073A (en) 1985-03-25 2000-07-04 Chiron Corporation Recombinant ricin toxin
EP0229108B1 (en) 1985-06-26 1990-12-27 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4870163A (en) 1985-08-29 1989-09-26 New York Blood Center, Inc. Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor
EP0222360A3 (en) 1985-11-12 1989-03-15 Biotherapeutics Inc. A method of producing a patient-specific cytotoxic reagent and composition
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
EP0226418B1 (en) 1985-12-06 1992-05-27 Cetus Oncology Corporation Anti-human ovarian cancer immunotoxins and methods of use thereof
US4962188A (en) 1985-12-06 1990-10-09 Cetus Corporation Recombinant ricin toxin A chain conjugates
US4831122A (en) 1986-01-09 1989-05-16 Regents Of The University Of Minnesota Radioimmunotoxins
JPS62190200A (ja) 1986-02-17 1987-08-20 Res Dev Corp Of Japan 抗腫瘍蛋白複合体およびその製造方法
US4894227A (en) 1986-08-01 1990-01-16 Cetus Corporation Composition of immunotoxins with interleukin-2
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4771128A (en) 1986-10-10 1988-09-13 Cetus Corporation Method of purifying toxin conjugates using hydrophobic interaction chromatography
US5019368A (en) 1989-02-23 1991-05-28 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
US4861581A (en) 1986-12-05 1989-08-29 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
US4963354A (en) 1987-01-21 1990-10-16 Genentech, Inc. Use of tumor necrosis factor (TNF) as an adjuvant
US4894225A (en) 1987-03-02 1990-01-16 Cetus Corporation Combination therapy using antitumor immunotoxins with tumor necrosis factor
NO881077L (no) 1987-03-11 1988-09-12 Univ Michigan Kjemo-radio-immuno-konjugater.
US4971792A (en) 1987-03-27 1990-11-20 The Wistar Institute Monoclonal antibodies against glycolipid antigens
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
EP0317641B1 (en) 1987-05-29 1993-03-17 Sagami Chemical Research Center Fused protein containing lymphotoxin
US4863726A (en) 1987-05-29 1989-09-05 Cetus Corporation Combination therapy using immunotoxins with interleukin-2
CA1341235C (en) 1987-07-24 2001-05-22 Randy R. Robinson Modular assembly of antibody genes, antibodies prepared thereby and use
EP0305967B1 (de) 1987-09-02 1993-05-05 Ciba-Geigy Ag Konjugate von Interferon alpha mit Immunglobulinen
US5017371A (en) 1988-01-06 1991-05-21 Amarillo Cell Culture Company, Incorporated Method for reducing side effects of cancer therapy
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US4867962A (en) 1988-02-26 1989-09-19 Neorx Corporation Functionally specific antibodies
CA1329119C (en) 1988-03-29 1994-05-03 Milton David Goldenberg Cytotoxic therapy
IE62463B1 (en) 1988-07-07 1995-02-08 Res Dev Foundation Immunoconjugates for cancer diagnosis and therapy
US5135736A (en) 1988-08-15 1992-08-04 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
US5099842A (en) * 1988-10-28 1992-03-31 Nellcor Incorporated Perinatal pulse oximetry probe
US5134075A (en) 1989-02-17 1992-07-28 Oncogen Limited Partnership Monoclonal antibody to novel antigen associated with human tumors
ZA902949B (en) 1989-05-05 1992-02-26 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US6750329B1 (en) 1989-05-05 2004-06-15 Research Development Foundation Antibody delivery system for biological response modifiers
US5332671A (en) 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
IE62496B1 (en) 1990-04-19 1995-02-08 Res Dev Foundation Antibody conjugates for treatment of neoplastic disease
US6306626B1 (en) 1990-04-27 2001-10-23 Research Development Foundation Anti-IgM monoclonal antibodies and methods of their use
IE912716A1 (en) 1990-08-14 1992-02-26 Res Dev Foundation Protein Structure of the Plant Toxin Gelonin
US6099842A (en) 1990-12-03 2000-08-08 The United States Of America As Represented By The Department Of Health And Human Services Recombinant immunotoxin composed of a single chain antibody reacting with the human transferrin receptor and diptheria toxin
DK0517895T3 (da) 1990-12-14 1997-04-07 Univ California Kimæriske kæder til receptorforbundne signaltransduktionsveje
DE69227519T2 (de) 1991-09-06 1999-06-02 Research Development Foundation, Carson City, Nev. Dna-sequenzen kodierend für das polypeptid gelonin
US5621083A (en) 1991-11-04 1997-04-15 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
WO1994026910A1 (en) 1993-05-12 1994-11-24 Xoma Corporation Immunotoxins comprising gelonin and an antibody
US5837491A (en) 1991-11-04 1998-11-17 Xoma Corporation Polynucleotides encoding gelonin sequences
US6599505B1 (en) 1992-04-10 2003-07-29 Research Development Foundation Immunotoxins directed against CD33 related surface antigens
US5851829A (en) * 1993-07-16 1998-12-22 Dana-Farber Cancer Institute Method of intracellular binding of target molecules
IL112372A (en) 1994-02-07 2001-08-26 Res Dev Foundation Non-viral vector for the delivery of genetic information to cells
US5942230A (en) 1994-05-06 1999-08-24 The United States Of America As Represented By The Department Of Health And Human Services Composition of immunotoxins and retinoids and use thereof
US5513296A (en) * 1994-06-08 1996-04-30 Holmes Products Corp. Air heater with angled PTC heaters producing diverging heated airflow
JP3033068B2 (ja) 1994-06-20 2000-04-17 富士写真光機株式会社 フィルム給送制御装置
GB9506466D0 (en) 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
IL116559A (en) * 1995-11-17 2005-11-20 Yissum Res Dev Co Chimeric protein consisting of a bacterial toxin and a myelin basic protein sequence
IL116436A (en) 1995-12-18 2006-12-31 Yissum Res Dev Co Fc?Á-PE CHIMERIC PROTEIN FOR TARGETED TREATMENT OF ALLERGY RESPONSES AND
US5851815A (en) 1996-03-19 1998-12-22 Idun Pharmaceuticals, Inc. MCH4 and MCH5, apoptotic proteases
IL118570A (en) * 1996-06-04 2007-06-17 Shai Yarkoni Use of a chimeric protein that includes Met – GnRH in the preparation of a pharmaceutical preparation for the treatment of adenocarcinoma or patocarcinoma
JP2001516210A (ja) 1997-02-28 2001-09-25 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 遺伝子治療による炎症細胞の自己調節されたアポトーシス
EP0893493A3 (de) 1997-07-21 2002-12-04 Aventis Pharma Deutschland GmbH Genetisch veränderte Zellen und deren Verwendung in der Prophylaxe oder Therapie von Erkrankungen
WO1999040198A2 (en) 1998-02-04 1999-08-12 Thromb-X N.V. Identification, production and use of staphylokinase derivatives with reduced immunogenicity and/or reduced clearance
IL137871A0 (en) * 1998-02-27 2001-10-31 Boehringer Ingelheim Pharma Self-regulated apoptosis of inflammatory cells by gene therapy
US6645490B2 (en) * 1998-03-02 2003-11-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Chimeric proteins with cell-targeting specificity and apoptosis-inducing activities
US6140066A (en) * 1998-03-24 2000-10-31 Lorberboum-Galski; Haya Methods of cancer diagnosis using a chimeric toxin
US20040009477A1 (en) 1998-04-03 2004-01-15 Invitrogen Corporation Methods for producing libraries of expressible gene sequences
EP1066309A4 (en) 1998-04-03 2005-10-19 Invitrogen Corp LIBRARIES OF EXPRESSIBLE GENESQUENCES
CA2324514A1 (en) 1998-04-03 1999-10-14 Invitrogen Corporation Methods for producing libraries of expressible gene sequences
US6835550B1 (en) 1998-04-15 2004-12-28 Genencor International, Inc. Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
CU22732A1 (es) 1998-08-14 2002-02-28 Ct Ingenieria Genetica Biotech Mutantes de estreptoquinasa
JP2002534959A (ja) 1998-12-08 2002-10-22 バイオベーション リミテッド 免疫原性タンパク質の改変方法
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
CA2396422A1 (en) 2000-01-06 2001-07-12 Monsanto Technology Llc Preparation of deallergenized proteins and permuteins
ES2292587T3 (es) 2000-04-22 2008-03-16 Pharmedartis Gmbh Agentes apoptoticos.
ZA200305980B (en) * 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
GB0116047D0 (en) 2001-06-29 2001-08-22 Implyx Ltd Peptide motif for therapy
DK1414471T3 (da) 2001-07-17 2012-07-16 Res Dev Foundation Terapeutiske midler omfattende pro-apoptotiske proteiner
US20040013691A1 (en) 2002-06-12 2004-01-22 Rosenblum Michael G. Immunotoxin as a therapeutic agent and uses thereof

Also Published As

Publication number Publication date
JP2004535202A (ja) 2004-11-25
IL159894A0 (en) 2004-06-20
CA2454048C (en) 2011-05-03
US7371723B2 (en) 2008-05-13
EP1414471A2 (en) 2004-05-06
US20120252097A1 (en) 2012-10-04
EP1414471B1 (en) 2012-06-13
NZ530582A (en) 2008-06-30
WO2003007889A3 (en) 2003-10-09
CN1555268B (zh) 2013-04-03
KR100891272B1 (ko) 2009-04-06
US7759091B2 (en) 2010-07-20
US8530225B2 (en) 2013-09-10
US20060280749A1 (en) 2006-12-14
US20030086919A1 (en) 2003-05-08
US20110002910A1 (en) 2011-01-06
AU2002327310B2 (en) 2006-09-28
KR20040038982A (ko) 2004-05-08
EP1414471A4 (en) 2005-12-28
US7101977B2 (en) 2006-09-05
US20090010917A1 (en) 2009-01-08
CN1555268A (zh) 2004-12-15
US8043831B2 (en) 2011-10-25
WO2003007889A2 (en) 2003-01-30
CA2454048A1 (en) 2003-01-30
IL159894A (en) 2010-05-17

Similar Documents

Publication Publication Date Title
DK1414471T3 (da) Terapeutiske midler omfattende pro-apoptotiske proteiner
NO20040402L (no) Peptidbaserte multimere malrettede kontrastmidler
NO20033556D0 (no) Farmasöytiske preparater
DK1427444T3 (da) West-nil-vaccine
NO20033549L (no) Terapeutiske bindingsmolekyler
DE60210864D1 (de) Modifiziertes fluoreszentes Protein
DE60226425D1 (de) Lösliches rage-protein
NO20034097D0 (no) Hormonerstatningsterapi
NO20035315D0 (no) Farmasöytiske kombinasjoner
DE60208982D1 (de) Fussbad
NO20035224D0 (no) Oftalmisk pirenzepingel
DE50200615D1 (de) Geminitenside
DE50209245D1 (de) Neuroprotektives medikament
NO20014597D0 (no) Fremgangsmåte
DE50200250D1 (de) Geminitenside
DE60114244D1 (de) Osteosynthesevorrichtung
NO20032963L (no) Peptidforbindelser
ATA5002002A (de) Vibrator
DE60237655D1 (de) Entwicklungsgerät
ZA200400228B (en) Therapeutic agents comprising pro-apoptotic proteins
DE60117001D1 (de) Nectin-3 proteine
DE10157913B4 (de) Therapietisch
NO20020794L (no) Meg-1-protein
SE0103854D0 (sv) Therapeutic agents
SE0103855D0 (sv) Therapeutic agents